Fundraising reaches $61 million over first five years
Pelotonia reached yet another fundraising record during the 2013 ride, as riders raised more than $19 million this year.
More than 6,700 riders and more than 2,300 volunteers from 41 states and nine countries rode up to 180 miles on one of four routes during the Aug. 10-11 event, though riders had through October to complete their fundraising activities. The official 2013 total of $19,007,104 was announced at a ceremony Dec. 5.
“To exceed $19 million in fundraising for our fifth ride is simply remarkable. Looking forward, we are on our way to generating more than $20 million annually,” said Tom Lennox, chief executive officer of Pelotonia. “As a cancer survivor, I couldn’t be more grateful for the selfless initiative taken by our riders and volunteers toward ending cancer. I am proud to lead a group of dedicated associates who are determined to provide an exceptional rider experience that has enabled Pelotonia to raise more than $61 million in five years for Ohio State’s cancer program.”
In partnership with Pelotonia’s sponsors, 100 percent of every rider-raised dollar through Pelotonia directly funds research at The Ohio State University Comprehensive Cancer Center – James Cancer Hospital and Solove Research Institute.
“Every year, I am humbled by the generosity and tenacious commitment of the thousands and thousands of Pelotonia riders and volunteers working to help us reach our goal of creating a cancer-free world,” said Michael Caligiuri, director of The Comprehensive Cancer Center and CEO of The James. “Pelotonia support has been integral to our ability to attract, support and retain brilliant clinician-scientists to Ohio State; support student and fellowship training in cancer research; purchase sophisticated research equipment critical to conducting cancer research; and funding the new big ideas in cancer research that will help us better understand the molecules and markers fueling each person’s unique cancer.”
Funds are allocated to four primary areas: a fellowship program, funding student researchers, “Idea Grants” that fund teams of researchers, and recruitment and retention of leading cancer researchers and programs.
Break-through cancer research funded by Pelotonia includes discoveries with an experimental drug called ibrutinib. The drug, developed by Pharmacyclics Inc., has potential as a safe and effective treatment alternative, with better outcomes and fewer side effects, for patients diagnosed with chronicle lymphocytic leukemia and mantel cell lymphoma.
The 2014 Pelotonia ride is scheduled for Aug. 8-10, 2014. Rider registration opened on Jan. 7 at pelotonia.org.